About this item:

813 Views | 298 Downloads

Author Notes:

Corresponding Author: Leon Bernal-Mizrachi, MD., Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University. 1365 Clifton Road, Room C1152B, Atlanta, GA, 30322, USA, Tel: 404-778-1670, Fax: 404 778-4755, lbernal@emory.edu


Research Funding:

L.H.B received funding support from the NIH (CA127910 and CA129968) and a GCCDSW, L.R. was supported by the National Institute of Health (NIH, CA94056, CA10073 and CA63417) and L.B-M received funding from the Crissey Hematology and Medical Oncology Research Fund.


  • XIAP
  • EBV
  • HTLV-1
  • HHV-8
  • lymphomas
  • Smac mimetics

The SMAC mimetic RMT5265.2HCL induces apoptosis in EBV AND HTLV-I associated lymphoma cells by inhibiting XIAP and promoting the mitochondrial release of cytochrome C and Smac


Journal Title:

Leukemia Research


Volume 36, Number 6


, Pages 784-790

Type of Work:

Article | Post-print: After Peer Review


The inhibitors of apoptosis (IAP) are important regulators of apoptosis. However, little is known about the capacity of Smac mimetics (IAP inhibitor) to overcome virally-associated-lymphoma’s (VAL) resistance to apoptosis. Here, we explored the pro-apoptotic effect of a novel Smac mimetic, RMT5265.2HCL (RMT) in VAL cells. RMT improved the sensitivity to apoptosis in EBV- and to some extend in HTLV-1- but not in HHV-8-VAL. Furthermore, we identified that RMT promotes caspase 3 and 9 cleavage by inhibiting XIAP and inducing the mitochondrial efflux of Smac and cytochrome C. This investigation further support exploring the use of Smac inhibitors in VAL.

Copyright information:

© 2012 Elsevier Ltd. All rights reserved.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommerical-NoDerivs 3.0 Unported License (http://creativecommons.org/licenses/by-nc-nd/3.0/).

Creative Commons License

Export to EndNote